Comparison of dual influenza and pneumococcal polysaccharide vaccination with influenza vaccination alone for preventing pneumonia and reducing mortality among the elderly: A meta-analysis

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 12, 2016, Pages 3056-3064

  Zhang, Yan Yang ^a   Tang, Xue Feng ^b,c   Du, Chang Hui ^d   Wang, Bin Bing ^e   Bi, Zhen Wang ^f   Dong, Bi Rong ^c  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b SICHUAN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c SICHUAN UNIVERSITY   (China)

^d Chengdu Center for Disease Control and Prevention   (China)

^e Anhui Center for Disease Control and Prevention   (China)

^f Shandong Center for Disease Control and Prevention   (China)

Author keywords

aged; influenza vaccine; meta analysis; mortality; pneumococcal vaccine; pneumonia

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

BIBLIOGRAPHIC DATABASE; HUMAN; INFLUENZA VACCINATION; LENGTH OF STAY; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; SYSTEMATIC REVIEW; AGED; COMPARATIVE STUDY; COMPLICATION; IMMUNOLOGY; INFLUENZA, HUMAN; PNEUMONIA, PNEUMOCOCCAL; PROCEDURES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LENGTH OF STAY; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VACCINATION;

EID: 84991219251     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1221552     Document Type: Review

References (47)

1. World Health Organization, Strategic Advisory Group of Experts (SAGE) Working Group. Background paper on influenza vaccines and immunization. 2012. Available at:http://www.who.int/entity/immunization/sage/meetings/2012/april/1_Background_Paper_Mar26_v13_cleaned.pdf?ua=1. Accessed:January 5, 2016.
2. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people:a systematic review. Lancet 2005; 366:1165-74; PMID:16198765; http://dx.doi.org/10.1016/S0140-6736(05)67339-4
3. Darvishian M, Gefenaite G, Turner RM, Pechlivanoglou P, Van der Hoek W, Van den Heuvel ER, Hak E. After adjusting for bias in meta-analysis seasonal influenza vaccine remains effective in community-dwelling elderly. J Clin Epidemiol 2014; 67:734-44; PMID:24768004; http://dx.doi.org/10.1016/j.jclinepi.2014.02.009
4. Palacios G, Hornig M, Cisterna D, Savji N, Bussetti AV, Kapoor V, Hui J, Tokarz R, Briese T, Baumeister E, et al. Streptococcus pneumoniae coinfection is correlated with the severity of H1N1 pandemic influenza. PLoS One 2009; 4:e8540; PMID:20046873; http://dx.doi.org/10.1371/journal.pone.0008540
5. Walter ND, Taylor TH, Shay DK, Thompson WW, Brammer L, Dowell SF, Moore MR, Active Bacterial Core Surveillance Team. Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis 2010; 50:175-83; PMID:20014948; http://dx.doi.org/10.1086/649208
6. Centers for Disease Control and Prevention (CDC). Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010; 59:1102-6; PMID:20814406
7. Ochoa-Gondar O, Vila-Corcoles A, Rodriguez-Blanco T, Gomez-Bertomeu F, Figuerola-Massana E, Raga-Luria X, Hospital-Guardiola I. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years:3 years of follow-up in the CAPAMIS study. Clin Infect Dis 2014; 58:909-17; PMID:24532544; http://dx.doi.org/10.1093/cid/ciu002
8. Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults:a systematic review of conclusions and assumptions. Vaccine 2009; 27:4891-904; PMID:19520205; http://dx.doi.org/10.1016/j.vaccine.2009.05.061
9. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Lee BY, Zimmerman RK. Modeling of cost effectiveness of pneumococcal conjugate vaccination strategies in U.S. older adults. Am J Prev Med 2013; 44:373-81; PMID:23498103; http://dx.doi.org/10.1016/j.amepre.2012.11.035
10. Isturiz R, Webber C. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine:CAPiTA, the community-acquired pneumonia immunization trial in adults. Hum Vaccin Immunother 2015; 11:1825-7; PMID:26076136; http://dx.doi.org/10.1080/21645515.2015.1043502
11. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114-25; PMID:25785969; http://dx.doi.org/10.1056/NEJMoa1408544
12. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T, Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥ 65 years:recommendations of the Advisory Committee on Immunization Practices (ACIP). MWR Morb Mortal Wkly Rep 2014; 63:822-5
13. Fedson DS, Liss C. Precise answers to the wrong question:prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004; 22:927-46; PMID:15161070; http://dx.doi.org/10.1016/j.vaccine.2003.09.027
14. Hollingsworth R, Isturiz R. Pneumococcal vaccination of older adults:conjugate or polysaccharide? Hum Vaccin Immunother 2014; 10:45-6; PMID:24018552; http://dx.doi.org/10.4161/hv.26330
15. Li C, Gubbins PO, Chen GJ. Prior pneumococcal and influenza vaccinations and in-hospital outcomes for community-acquired pneumonia in elderly veterans. J Hosp Med 2015; 10:287-93; PMID:25676363; http://dx.doi.org/10.1002/jhm.2328
16. Gilchrist SA, Nanni A, Levine O. Benefits and effectiveness of administering pneumococcal polysaccharide vaccine with seasonal influenza vaccine:an approach for policymakers. Am J Public Health 2012; 102:596-605; PMID:22397339; http://dx.doi.org/10.2105/AJPH.2011.300512
17. Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine 1999; 17:S91-3; PMID:10471189; http://dx.doi.org/10.1016/S0264-410X(99)00114-0
18. Christenson B, Pauksen K, Sylvan SP. Effect of influenza and pneumococcal vaccines in elderly persons in years of low influenza activity. Virol J 2008; 5:52; PMID:18442371; http://dx.doi.org/10.1186/1743-422X-5-52
19. Grilli G, Fuiano L, Biasio LR, Pregliasco F, Plebani A, Leibovitz M, Ugazio AG, Vacca F, Profeta ML. Simultaneous influenza and pneumococcal vaccination in elderly individuals. Eur J Epidemiol 1997; 13:287-91; PMID:9258527; http://dx.doi.org/10.1023/A:1007398606807
20. Domínguez A, Castilla J, Godoy P, Delgado-Rodríguez M, Saez M, Soldevila N, Astray J, Mayoral JM, Martín V, Quintana JM, et al. Effectiveness of vaccination with 23-valent pneumococcal polysaccharide vaccine in preventing hospitalization with laboratory confirmed influenza during the 2009–2010 and 2010–2011 seasons. Hum Vaccin Immunother 2013; 9:865-73; http://dx.doi.org/10.4161/hv.23090
21. Vila-Corcoles A, Ochoa-Gondar O, Rodriguez-Blanco T, de Diego-Cabanes C, Satue-Gracia E, Vila-Rovira A, Torrente Fraga C, EPIVAC Research Group. Evaluating clinical effectiveness of pneumococcal vaccination in preventing stroke:the CAPAMIS Study, 3-year follow-up. J Stroke Cerebrovasc Dis 2014; 23:1577-84; PMID:24656243; http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2013.12.047
22. Assendelf WJ, Scholten RJ, Offringa M. Pneumococcal vaccination for the elderly in The Netherlands? Assessment of the quality and content of available comparative studies. Neth J Med 2004; 62:36-44; PMID:15127829
23. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Läärä E, Leinonen M, Kivelä SL, Mäkelä PH. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999; 17:2493-500; PMID:10418894; http://dx.doi.org/10.1016/S0264-410X(99)00069-9
24. Furumoto A, Ohkusa Y, Chen M, Kawakami K, Masaki H, Sueyasu Y, Iwanaga T, Aizawa H, Nagatake T, Oishi K. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26:4284-9; PMID:18585831; http://dx.doi.org/10.1016/j.vaccine.2008.05.037
25. Chan TC, Hung IF, Luk JK, Shea YF, Chan FH, Woo PC, Chu LW. Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1). J Am Med Dir Assoc 2012; 13:698-703; PMID:22722051; http://dx.doi.org/10.1016/j.jamda.2012.05.009
26. Chang YC, Chou YJ, Liu JY, Yeh TF, Huang N. Additive benefits of pneumococcal and influenza vaccines among elderly persons aged 75 years or older in Taiwan–a representative population-based comparative study. J Infect 2012; 65:231-8; PMID:22561486; http://dx.doi.org/10.1016/j.jinf.2012.04.014
27. Kawakami K, Ohkusa Y, Kuroki R, Tanaka T, Koyama K, Harada Y, Iwanaga K, Yamaryo T, Oishi K. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 2010; 28:7063-9; PMID:20723631; http://dx.doi.org/10.1016/j.vaccine.2010.08.010
28. Christenson B, Hedlund J, Lundbergh P, Ortqvist A. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004; 23:363-8; PMID:15065822; http://dx.doi.org/10.1183/09031936.04.00063504
29. Hung IF, Leung AY, Chu DW, Leung D, Cheung T, Chan CK, Lam CL, Liu SH, Chu CM, Ho PL, et al. Prevention of acute myocardial infarction and stroke among elderly persons by dual pneumococcaland influenza vaccination:a prospective cohort study. Clin Infect Dis 2010; 51:1007-16; PMID:20887208; http://dx.doi.org/10.1086/656587
30. Wells G, Shea B, O'Connell J, Robertson J, Peterson V, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Available at:http://www.ohri.ca/programs/clinical_epidemiology/nos_manual.pdf
31. Frenck RW, Jr, Gurtman A, Rubino J, Smith W, van Cleeff M, Jayawardene D, Giardina PC, Emini EA, Gruber WC, Scott DA, et al. Randomized, controlled trial of a 13-valent pneumococcal conjugate vaccine administered concomitantly with an influenza vaccine in healthy adults. Clin Vaccine Immunol 2012; 19:1296-303; PMID:22739693; http://dx.doi.org/10.1128/CVI.00176-12
32. Socan M, Frelih T, Janet E, Petras T, Peternelj B. Reactions after pneumococcal vaccine alone or in combination with influenza vaccine. Vaccine 2004; 22:3087-91; PMID:15297059; http://dx.doi.org/10.1016/j.vaccine.2004.02.003
33. Shiramoto M, Hanada R, Juergens C, Shoji Y, Yoshida M, Ballan B, Cooper D, Gruber WC, Scott DA, Schmoele-Thoma B. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother 2015; 11:2198-206; PMID:26176163; http://dx.doi.org/10.1080/21645515.2015.1030550
34. Jackson LA, Gurtman A, van Cleeff M, Jansen KU, Jayawardene D, Devlin C, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine 2013; 31:3577-84; PMID:23688526; http://dx.doi.org/10.1016/j.vaccine.2013.04.085
35. Cai L, Uchiyama H, Yanagisawa S, Kamae I. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan. Kobe J Med Sci 2006; 52:97-109; PMID:16855372
36. You JH, Wong WC, Ip M, Lee NL, Ho SC. Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities. J Epidemiol Community Health 2009; 63:906-11; PMID:19608558; http://dx.doi.org/10.1136/jech.2008.081885
37. Smith KJ, Wateska AR, Nowalk MP, Raymund M, Nuorti JP, Zimmerman RK. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012; 307:804-12; PMID:22357831
38. Ament A, Baltussen R, Duru G, Rigaud-Bully C, de Graeve D, Ortqvist A, Jönsson B, Verhaegen J, Gaillat J, Christie P, et al. Cost-effectiveness of pneumococcal vaccination of older people:a study in 5 western European countries. Clin Infect Dis 2000; 31:444-50; PMID:10987703; http://dx.doi.org/10.1086/313977
39. Fedson DS, Guppy MJ. Pneumococcal vaccination of older adults:conjugate or polysaccharide? Hum Vaccin Immunother 2013; 9:1382-4; PMID:23732892; http://dx.doi.org/10.4161/hv.24692
40. Evers SM, Ament AJ, Colombo GL, Konradsen HB, Reinert RR, Sauerland D, Wittrup-Jensen K, Loiseau C, Fedson DS. Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly:an update for 10 Western European countries. Eur J Clin Microbiol Infect Dis 2007; 26:531-40; PMID:17570001; http://dx.doi.org/10.1007/s10096-007-0327-z
41. Raboisson D, Mounié M, Maigné E. Diseases, reproductive performance, and changes in milk production associated with subclinical ketosis in dairy cows:a meta-analysis and review. J Dairy Sci 2014; 97:7547-63; PMID:25306269; http://dx.doi.org/10.3168/jds.2014-8237
42. Zheng Y, Lu C, Wei S, Li Y, Long L, Yin P. Association of red blood cell transfusion and in-hospital mortality in patients admitted to the intensive care unit:a systematic review and meta-analysis. Crit Care 2014; 18:515. doi:10.1186/s13054-014-0515-z; PMID:25394759
43. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer:a meta-analysis of cohort studies. Br J Cancer 2007; 97:1005-8; PMID:17700568
44. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions:explanation and elaboration. Ann Intern Med 2009; 151:W65-94; PMID:19622512; http://dx.doi.org/10.7326/0003-4819-151-4-200908180-00136
45. Protocol for case-control studies of influenza vaccine effectiveness in the European Union and European Economic Area Member States. ECDC Technical Document. Available at:http://ecdc.europa.eu/en/publications/Publications/0907_TED_Influenza_AH1N1_Measuring_Influenza_Vaccine_Effectiveness_Protocol_Case_Control_Studies.pdf. Accessed:June1, 2016
46. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011; 343:d4002; PMID:21784880; http://dx.doi.org/10.1136/bmj.d4002
47. Wells GA, Sultan SA, Chen L, Khan M, Coyle D. Indirect treatment comparison [computer program]. Version 1.0. Canadian Agency for Drugs and Technologies in Health; Ottawa, 2009